Method for evaluating curative effect of compound glutamine enteric capsule
Through prospective, randomized controlled and double-blind clinical trials, the efficacy of compound glutamine enteric capsules in patients with gastric cancer and intestinal cancer was evaluated, and the problem of lack of effective strategies for the treatment of chemotherapy-related mucositis was solved, and the gastrointestinal tract was achieved Scientific assistance to the use of drugs for tumor prevention.
Patent Information
- Application Number
- CN202411268382.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing technology lacks effective strategies to prevent and treat chemotherapy-related mucositis. Chemotherapy drugs cause damage to the gastrointestinal mucosal, resulting in a decrease in patient quality of life and treatment tolerance. There is a lack of prospective randomized controlled clinical studies to verify that glutamine is related to chemotherapy. Preventive and therapeutic value in mucositis.
Through prospective, randomized controlled, double-blind clinical trials, a method to evaluate the efficacy of compound glutamine enteric-coated capsules was designed. The grouping design includes primary and secondary prevention, and observation of compound glutamine enteric-coated capsules and placebo. The efficacy and safety of controls in patients with gastric and intestinal cancer were compared, and observation endpoints and indicators were set, and data statistics and analysis were carried out.
提供了一种科学的方法来评价复方谷氨酰胺肠溶胶囊在预防胃肠道肿瘤中的疗效,从而辅助胃肠道肿瘤预防用药,准确评估其在化疗相关性消化道粘膜炎中的疗效和安全性,提高了对化疗相关性粘膜炎的预防和治疗的科学性。
Smart Images

Figure CN119074964A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of efficacy evaluation of compound glutamine enteric-coated capsules, in particular to a method for evaluating the efficacy of compound glutamine enteric-coated capsules. Background Art
[0002] Gastric cancer and intestinal cancer are the most common digestive tract tumors. Fluorouracil-based chemotherapy plays a very important role in the adjuvant treatment and palliative chemotherapy of gastrointestinal tumors. While chemotherapy drugs improve the survival of patients with gastric cancer and intestinal cancer, they often cause obvious adverse reactions to the digestive tract, such as chemotherapy-related oral mucositis, abdominal pain, diarrhea, constipation, etc. Among them, chemotherapy-related oral mucositis, diarrhea and abdominal pain are the most common, which seriously affect the quality of life of patients and treatment tolerance and efficacy. Some patients interrupt treatment due to intolerance, and the incidence rate is as high as 50%-80%.
[0003] The mechanism of chemotherapy-induced gastrointestinal mucosal damage has not been fully confirmed. Many studies have shown that chemotherapy can lead to changes in both gastrointestinal function and structure: (1) Chemotherapy drugs can disrupt the cell balance of the intestinal wall, causing loss, atrophy, necrosis and inflammation of the intestinal mucosal epithelium with a faster metabolism, reducing the intestinal absorption efficiency of water; (2) Chemotherapy drugs inhibit the secretory activity of the patient's small intestine and colorectum, increase the permeability of the intestinal mucosa, and inhibit the activity of intestinal enzymes; (3) Damage to the gastrointestinal mucosa causes bacterial displacement, ultimately leading to a decrease in probiotics and intestinal flora disorder, especially a decrease in the number of bifidobacteria and Escherichia coli, which are absolutely dominant. The higher the concentration of chemotherapy drugs, the more obvious the inhibition; (4) Surgery and chemotherapy stimulate the release of a large number of inflammatory factors, affecting the patient's immune regulation function. Due to the diversity of chemotherapy drugs and the complexity of their pathogenesis, clinicians lack knowledge and experience with them, and there is currently a lack of unified and effective prevention and treatment strategies. The treatment of chemotherapy-related mucositis needs to aim at controlling symptoms, reducing pain, repairing mucosae, and preventing secondary infections. Glutamine and proecological preparations are currently the two most commonly used nutritional preparations in clinical practice that can effectively improve patients' symptoms.
[0004] Glutamine is a non-essential amino acid, accounting for about 60% of the total free amino acids in the human body. In the case of malignant tumors, long-term hunger and other conditions, the body's demand for glutamine increases significantly. If the body's own synthesis is insufficient, glutamine deficiency will occur, which will trigger or aggravate a series of pathological and physiological reactions. Glutamine has multiple physiological functions. Among them, as the main nutrient source for intestinal epithelial cells, glutamine is of great significance to the maintenance of their structure and function. It can stimulate the absorption of electrolytes and nutrients in the small intestine and prevent the occurrence of enteritis symptoms such as diarrhea. Therefore, when the concentration of glutamine decreases, the gastrointestinal mucosal epithelium often atrophies. Under the action of chemotherapy drugs, the gastrointestinal mucosa is very susceptible to damage. Studies have shown that oral glutamine is beneficial to protect the integrity of the mucosal epithelium during treatment, counteract chemotherapy damage to mucosal cells, reduce the gastrointestinal side effects of chemotherapy, and promote the proliferation of immune cells. Adding glutamine to parenteral nutrition can better maintain nitrogen balance and reduce the incidence of infection-related complications.
[0005] During anti-tumor chemotherapy, studies on oral glutamine supplementation have shown that it can reduce chemoradiotherapy-related mucositis. The clinical evidence is mainly for oral mucositis, and most of them are small sample studies. Only small sample clinical trials have explored the role of glutamine in chemical mucositis, and there is a lack of prospective randomized controlled clinical studies to further verify its preventive and therapeutic value in chemical mucositis. The present invention proposes a method for evaluating the efficacy of compound glutamine enteric-coated capsules, which aims to observe the efficacy and safety of compound glutamine enteric-coated capsules in primary and secondary prevention of chemotherapy-related mucositis in patients with gastric cancer and intestinal cancer through prospective, randomized controlled, double-blind clinical trials in parallel with placebo. Summary of the invention
[0006] The object of the present invention is to provide a method for evaluating the efficacy of compound glutamine enteric-coated capsules to solve the problems in the above-mentioned background technology.
[0007] To achieve the above object, the present invention provides the following technical solution: a method for evaluating the efficacy of compound glutamine enteric-coated capsules, comprising the following steps:
[0008] S1, establish primary prevention inclusion criteria and secondary prevention inclusion criteria;
[0009] S2, patients who meet the inclusion criteria for primary prevention were randomly divided into group A and group B at a 1:1 ratio. Group A first took compound glutamine enteric-coated capsules and then took placebo, and group B first took placebo and then took compound glutamine enteric-coated capsules. Each group had its own before and after comparison.
[0010] S3, patients who meet the inclusion criteria for secondary prevention were randomly divided into group C and group D at a 1:1 ratio. Group C received compound glutamine enteric-coated capsules, and group D received placebo.
[0011] S4, set observation endpoints and observation indicators, conduct efficacy evaluation, and perform statistics, processing and analysis on the data.
[0012] Preferably, the primary prevention inclusion criteria are as follows:
[0013] (1) Patients aged between 18 and 75 years old, regardless of gender;
[0014] (2) Pathologically diagnosed as gastric adenocarcinoma or colorectal adenocarcinoma;
[0015] (3) Patients who plan to receive chemotherapy containing platinum or irinotecan can also receive targeted drugs at the same time; they have not received any other anti-tumor related treatments before the start of treatment;
[0016] (4) The patient planned to receive at least 2 cycles of the same chemotherapy regimen;
[0017] (5) WH0-PS score of 0-2;
[0018] (6) Good organ function, including adequate bone marrow reserve function, good liver and kidney function: absolute neutrophil count ≥ 1.5 × 109 / L; platelet count ≥ 75 × 109 / L; serum total bilirubin ≤ 1 × upper limit of normal value; AST and ALT ≤ 2.5 × upper limit of normal value; serum creatinine (Cr) ≤ 1.5 × upper limit of normal value;
[0019] (7) Voluntarily sign the informed consent form.
[0020] Preferably, the inclusion criteria for secondary prevention are as follows:
[0021] (1) Patients aged between 18 and 75 years old, regardless of gender;
[0022] (2) Pathologically diagnosed as gastric adenocarcinoma or colorectal adenocarcinoma;
[0023] (3) Patients who have received standard chemotherapy containing platinum or irinotecan for no more than 2 cycles and who had grade I to III diarrhea in the previous cycle and recovered to grade 0 after symptomatic treatment;
[0024] (4) The patient plans to receive chemotherapy with the same regimen and dose as the previous cycle;
[0025] (5) WH0-PS score of 0-2;
[0026] (6) Good organ function, including adequate bone marrow reserve function, good liver and kidney function: absolute neutrophil count ≥ 1.5 × 109 / L; platelet count ≥ 75 × 109 / L; serum total bilirubin ≤ 1 × upper limit of normal value; AST and ALT ≤ 2.5 × upper limit of normal value; serum creatinine (Cr) ≤ 1.5 × upper limit of normal value;
[0027] (7) Voluntarily sign the informed consent form.
[0028] Preferably, the medications of Group A and Group B are as follows:
[0029] Group A: 3 tablets of compound glutamine enteric-coated capsules tid, starting from the first day of chemotherapy and continuing for 21 days, followed by a wash-out period and then taking the same dose of placebo, the whole cycle is 42 days;
[0030] Group B: 3 tablets of placebo tid, starting from the first day of chemotherapy and continuing for 21 days. Then after a wash-out period, the same dose of compound glutamine enteric-coated capsules was taken. The whole cycle was 42 days.
[0031] Preferably, the washout period is ≤14 days.
[0032] Preferably, the medications of Group C and Group D are as follows:
[0033] Group C: chemotherapy with the same regimen and the same dose as the previous cycle + 3 tablets of compound glutamine enteric-coated capsules tid, 21 days;
[0034] Group D: chemotherapy with the same regimen and same dose as in the previous cycle + 3 tablets of placebo tid, for 21 days.
[0035] Preferably, the observation endpoints include:
[0036] (1) Primary study endpoint: overall incidence of chemotherapy-related diarrhea ≥ grade 1;
[0037] (2) Secondary endpoints: the overall incidence of all gastrointestinal adverse events ≥ Grade 1 except diarrhea; the overall incidence of all gastrointestinal adverse events Grade G3 / 4;
[0038] (3) Exploratory study endpoints: changes in patients' quality of life; changes in IBS-SSS scores; changes in enteritis-related serum inflammatory factors and intestinal flora.
[0039] Preferably, the observation indicators include:
[0040] (1) Baseline level: gender, age, PS score, tumor differentiation, stage, biochemical indicators, and fecal flora distribution;
[0041] (2) Evaluation of gastrointestinal adverse events during chemotherapy: the first time, number, frequency, duration, severity, etc. of symptoms such as vomiting, abdominal pain, diarrhea, constipation, and anorexia;
[0042] (3) Fecal flora ratio detection and intestinal related inflammatory factor detection before and after treatment;
[0043] (4) Treatment status: treatment method, duration of remission, recurrence, intervention-related side effects, and other chemotherapy-related adverse reactions.
[0044] Preferably, the efficacy evaluation includes:
[0045] (1) The incidence and severity of chemotherapy-related gastrointestinal reactions;
[0046] (2) patient quality of life assessment and weight change;
[0047] (3) Changes in stool flora before and after;
[0048] (4) Comparison of intestinal inflammation-related factors in serum and stool.
[0049] Preferably, the statistical hypothesis tests of Group A and Group B, and Group C and Group D involved in the primary prevention and secondary prevention need to answer two independent questions, and the two hypothesis tests are performed at a significance level of bilateral α=0.05, and the required sample sizes will also be calculated separately.
[0050] The present invention has at least the following beneficial effects:
[0051] The present invention provides a method for evaluating the efficacy of compound glutamine enteric-coated capsules. Patients are grouped according to the primary prevention inclusion criteria and the secondary prevention inclusion criteria. The primary prevention adopts a crossover trial design, and the secondary prevention adopts a parallel control design. This can more accurately evaluate the efficacy of compound glutamine enteric-coated capsules for preventing gastrointestinal tumors, thereby scientifically assisting the use of drugs for gastrointestinal tumor prevention. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 This is a diagram of the medication scheme for Group A and Group B of the present invention;
[0053] Figure 2 This is a diagram of the medication regimen for Group C and Group D of the present invention. DETAILED DESCRIPTION
[0054] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0055] Example
[0056] The present invention aims at patients with gastric cancer and intestinal cancer who are undergoing chemotherapy, and evaluates the efficacy and safety of compound glutamine enteric-coated capsules compared with placebo in primary and secondary prevention of chemotherapy-related gastrointestinal mucositis; and analyzes the differences in changes in intestinal inflammatory factors, flora and quality of life in patients in the compound glutamine enteric-coated capsules group and the control group.
[0057] The method for evaluating the efficacy of compound glutamine enteric-coated capsules for preventing gastrointestinal tumors provided by the present invention comprises the following steps:
[0058] S1, establish primary prevention inclusion criteria and secondary prevention inclusion criteria;
[0059] S2, patients who meet the inclusion criteria for primary prevention were randomly divided into group A and group B at a 1:1 ratio. Group A first took compound glutamine enteric-coated capsules and then took placebo, and group B first took placebo and then took compound glutamine enteric-coated capsules. Each group had its own before and after comparison.
[0060] S3, patients who meet the inclusion criteria for secondary prevention were randomly divided into group C and group D at a 1:1 ratio. Group C received compound glutamine enteric-coated capsules, and group D received placebo.
[0061] S4, set observation endpoints and observation indicators, conduct efficacy evaluation, and perform statistics, processing and analysis on the data.
[0062] The details are as follows:
[0063] 1. Research subjects:
[0064] 1. Primary prevention research
[0065] 1.1 Inclusion criteria:
[0066] (1) Patients aged between 18 and 75 years old, regardless of gender;
[0067] (2) Pathologically diagnosed as gastric adenocarcinoma or colorectal adenocarcinoma;
[0068] (3) Patients who plan to receive chemotherapy containing platinum or irinotecan can also receive targeted drugs at the same time; they have not received any other anti-tumor related treatments before the start of treatment;
[0069] (4) The patient planned to receive at least 2 cycles of the same chemotherapy regimen;
[0070] (5) WH0-PS score of 0-2;
[0071] (6) Good organ function, including adequate bone marrow reserve function, good liver and kidney function: absolute neutrophil count ≥ 1.5 × 109 / L; platelet count ≥ 75 × 109 / L; serum total bilirubin ≤ 1 × upper limit of normal value; AST and ALT ≤ 2.5 × upper limit of normal value; serum creatinine (Cr) ≤ 1.5 × upper limit of normal value;
[0072] (7) Voluntarily sign the informed consent form.
[0073] 1.2 Exclusion criteria:
[0074] Nutritional screening PG-SGA score>9 or severe malnutrition (weight loss>10% or blood albumin<30g / L or body mass index<18.5kg / m2);
[0075] (1) Nutritional screening PG-SGA score > 9 or severe malnutrition (weight loss > 10% or serum albumin < 30 g / L or body mass index < 18.5 kg / m2);
[0076] (2) Severe heart, lung and brain diseases, combined with chronic hepatitis, cirrhosis, chronic nephritis, renal insufficiency, etc.;
[0077] (3) concurrent infection-related fever;
[0078] (4) Patients known to be allergic to or intolerant of any component used in the study;
[0079] (5) Patients with long-term diarrhea, abdominal pain, constipation or other gastrointestinal diseases or those with NCI CTCAE 4.0 grade II gastrointestinal reactions before chemotherapy;
[0080] (6) concurrently receiving other treatments that may cause diarrhea, such as radiotherapy;
[0081] (7) Those who take microecological regulation drugs such as Jinshuangqi, Mommy Love, and Changtai Oral Liquid
[0082] (8) Those taking Chinese medicine or antibiotics
[0083] (9) Any person who hinders the signing or understanding of the informed consent form.
[0084] (10) Participants in other clinical trials.
[0085] 2. Secondary prevention studies
[0086] 2.1 Inclusion criteria:
[0087] (1) Patients aged between 18 and 75 years old, regardless of gender;
[0088] (2) Pathologically diagnosed as gastric adenocarcinoma or colorectal adenocarcinoma;
[0089] (3) Patients who have received standard chemotherapy containing platinum or irinotecan for no more than 2 cycles and who had grade I to III diarrhea in the previous cycle and recovered to grade 0 after symptomatic treatment;
[0090] (4) The patient plans to receive chemotherapy with the same regimen and dose as the previous cycle;
[0091] (5) WH0-PS score of 0-2;
[0092] (6) Good organ function, including adequate bone marrow reserve function, good liver and kidney function: absolute neutrophil count ≥ 1.5 × 109 / L; platelet count ≥ 75 × 109 / L; serum total bilirubin ≤ 1 × upper limit of normal value; AST and ALT ≤ 2.5 × upper limit of normal value; serum creatinine (Cr) ≤ 1.5 × upper limit of normal value;
[0093] (7) Voluntarily sign the informed consent form.
[0094] 2.2 Exclusion criteria:
[0095] (1) Nutritional screening PG-SGA score > 9 or severe malnutrition (weight loss > 10% or serum albumin < 30 g / L or body mass index < 18.5 kg / m2)
[0096] (2) Severe heart, lung and brain diseases, combined with chronic hepatitis, cirrhosis, chronic nephritis, renal insufficiency, etc.;
[0097] (3) concurrent infection-related fever;
[0098] (4) Patients known to be allergic to or intolerant of any component used in the study;
[0099] (5) Patients with long-term abdominal pain, diarrhea, constipation or other digestive tract diseases or those who still have NCI CTCAE4.0>I diarrhea before chemotherapy;
[0100] (6) concurrently receiving other treatments that may cause diarrhea, such as radiotherapy;
[0101] (7) Those who take microecological regulation drugs such as Jinshuangqi, Mami Love, and Changtai oral liquid;
[0102] (8) Those taking traditional Chinese medicine or antibiotics;
[0103] (9) Those who hinder the signing and understanding of informed consent.
[0104] (10) Participants in other clinical trials.
[0105] 3. Criteria for termination of study treatment
[0106] Termination of study treatment does not mean withdrawal from the study. Subjects who terminate study treatment should continue to complete the remaining study visits as required by the protocol. Subjects must terminate study medication if any of the following situations occur:
[0107] (1) The subject requests to terminate the study drug treatment;
[0108] (2) The subject becomes pregnant during the study;
[0109] (3) The occurrence of any clinical AE, laboratory test abnormality, or other medical condition may result in the subject no longer benefiting from continued study treatment;
[0110] (4) The overall deterioration of health status makes it impossible to continue participating in the trial;
[0111] (5) After enrollment, it is found that the subject is ineligible, non-compliant, or has significant deviations from the protocol;
[0112] (6) Lost to follow-up;
[0113] (7) Death of the subject;
[0114] (8) Other reasons that the investigator believes cannot continue the study treatment;
[0115] 4. Criteria for exiting the study
[0116] Subjects may withdraw from the trial voluntarily at any time, or the investigator or sponsor may request them to withdraw from the trial for safety or behavioral reasons, or if they are unable to comply with the study visit times or procedures required by the protocol at their research center.
[0117] Reasons for subjects to withdraw from the study may include:
[0118] (1) The subject withdraws the informed consent to participate in the study and refuses further follow-up;
[0119] (2) Clinical adverse events, laboratory abnormalities, or concurrent diseases occur, and the investigators believe that continued participation in the study is not in the best interests of the subjects;
[0120] (3) Other circumstances that the researcher deems necessary for the subject to withdraw from the study, such as when the subject loses the ability to freely express his or her will due to imprisonment or isolation, or when there is a significant violation of the protocol;
[0121] (4) lost to follow-up;
[0122] (5) Death of the subject.
[0123] 2. Experimental plan
[0124] 1. Primary prevention:
[0125] Patients who meet the criteria are randomly divided into group A (first compound glutamine enteric-coated capsules and then placebo) and group B (first placebo and then compound glutamine enteric-coated capsules) in a 1:1 ratio, with self-control before and after, and each patient is observed for 42 days. The flow chart is as follows Figure 1 As shown, the medications for Group A and Group B were as follows:
[0126] Group A: 3 tablets of compound glutamine enteric-coated capsules tid, starting from the first day of chemotherapy and continuing for 21 days, followed by a wash-out period and then taking the same dose of placebo, the whole cycle is 42 days;
[0127] Group B: 3 tablets of placebo tid, starting from the first day of chemotherapy and continuing for 21 days. Then after a wash-out period, the same dose of compound glutamine enteric-coated capsules was taken. The whole cycle was 42 days, and the wash-out period was ≤14 days.
[0128] 2. Secondary prevention:
[0129] Patients who met the criteria were randomly divided into group C (compound glutamine enteric-coated capsule group) and group D (placebo group) in a 1:1 ratio, and each patient was observed for 21 days. Figure 2 As shown, the medications for Group C and Group D were as follows:
[0130] Group C: chemotherapy with the same regimen and the same dose as the previous cycle + 3 tablets of compound glutamine enteric-coated capsules tid, 21 days;
[0131] Group D: chemotherapy with the same regimen and same dose as in the previous cycle + 3 tablets of placebo tid, for 21 days.
[0132] 3. Observation endpoint:
[0133] (1) Primary study endpoint: overall incidence of chemotherapy-related diarrhea ≥ grade 1 (according to NCI CTCAE version 5.0);
[0134] (2) Secondary endpoints: the overall incidence of all gastrointestinal adverse events ≥ Grade 1 except diarrhea (including oral mucositis, vomiting, abdominal pain, dysphagia and others, according to NCI CTCAE version 5.0); the overall incidence of all gastrointestinal adverse events Grade G3 / 4;
[0135] (3) Exploratory study endpoints: changes in patients' quality of life; changes in IBS-SSS scores; changes in enteritis-related serum inflammatory factors and intestinal flora.
[0136] 4. Observation indicators:
[0137] (1) Baseline level: gender, age, PS score, tumor differentiation, stage, biochemical indicators, and fecal flora distribution;
[0138] (2) Evaluation of gastrointestinal adverse events during chemotherapy: the first time, number, frequency, duration, severity, etc. of symptoms such as vomiting, abdominal pain, diarrhea, constipation, and anorexia;
[0139] (3) Fecal flora ratio detection and intestinal related inflammatory factor detection before and after treatment;
[0140] (4) Treatment status: treatment method, duration of remission, recurrence, intervention-related side effects, and other chemotherapy-related adverse reactions.
[0141] V. Efficacy evaluation:
[0142] (1) The incidence and severity of chemotherapy-related gastrointestinal reactions;
[0143] (2) patient quality of life assessment and weight change;
[0144] (3) Changes in stool flora before and after;
[0145] (4) Comparison of intestinal inflammation-related factors in serum and stool.
[0146] 6. Data statistics, processing and analysis:
[0147] (1) Sample size calculation:
[0148] The statistical hypothesis tests of Group A and Group B, Group C and Group D involved in primary prevention and secondary prevention in this application need to answer two independent questions, so the two hypothesis tests will be conducted at a significance level of bilateral α=0.05, and the required sample sizes will be calculated separately. The null hypothesis of the two comparisons is that there is no difference in the incidence of adverse events between the two groups (Group A vs. Group B and Group C vs. Group D). If the P value corresponding to the statistic is less than or equal to 0.05, the null hypothesis is rejected and the alternative hypothesis that there is a difference in the incidence of adverse events between the two groups (Group A vs. Group B and Group C vs. Group D) is accepted.
[0149] (2) Primary prevention:
[0150] A crossover trial design was adopted, and the difference in the proportion of adverse events of interest in subjects after treatment with the two regimens was pre-set to be 14%, with a corresponding standard deviation of 0.5, and the incidence of adverse events in the placebo group was pre-set to 40%. The superiority margin was set to 0.04, the test level was 1-sided 0.025, and when the ratio between the two groups was 1:1, 98 subjects could provide 80% confidence to detect differences between the groups. Taking into account the occurrence of dropouts and loss of follow-up and breaking the blind, the sample size was expanded by 10%, and the total number of samples was 108.
[0151] (3) Secondary prevention:
[0152] A parallel control design was adopted. The incidence of diarrhea in the placebo group was pre-set to 85%, which could be reduced by about 40% in the experimental group, and the incidence of diarrhea in the experimental group was pre-set to 50%. The superiority margin was set to 0.08, the test level was unilateral 0.025, and the ratio between the two groups was 1:1. 82 subjects could provide 80% confidence to detect differences between the groups. Taking into account the occurrence of dropouts and loss of follow-up and breaking the blind, the sample size was expanded by 10%, and the total sample number was 90 cases.
[0153] The above sample sizes were calculated using SAS9.4.
[0154] The above shows and describes the basic principles, main features and advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and that the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention.
[0155] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for evaluating the efficacy of compound glutamine enteric-coated capsules. It is characterized in that The following steps are involved: S1, establish primary prevention inclusion criteria and secondary prevention inclusion criteria; S2, patients who meet the inclusion criteria for primary prevention were randomly divided into group A and group B at a 1:1 ratio. Group A first took compound glutamine enteric-coated capsules and then took placebo, and group B first took placebo and then took compound glutamine enteric-coated capsules. Each group had its own before and after comparison. S3, patients who meet the inclusion criteria for secondary prevention were randomly divided into group C and group D at a 1:1 ratio. Group C received compound glutamine enteric-coated capsules, and group D received placebo. S4, set observation endpoints and observation indicators, conduct efficacy evaluation, and perform statistics, processing and analysis on the data.
2. A method for evaluating the efficacy of compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The inclusion criteria for primary prevention are as follows: (1) Patients aged between 18 and 75 years old, regardless of gender; (2) Pathologically diagnosed as gastric adenocarcinoma or colorectal adenocarcinoma; (3) Patients who plan to receive chemotherapy containing platinum or irinotecan can also receive targeted drugs at the same time; they have not received any other anti-tumor related treatments before the start of treatment; (4) The patient planned to receive at least 2 cycles of the same chemotherapy regimen; (5) WH0-PS score of 0-2; (6) Good organ function, including adequate bone marrow reserve function, good liver and kidney function: absolute neutrophil count ≥ 1.5 × 10 9 / L; platelet count ≥75×10 9 / L; serum total bilirubin ≤1×upper limit of normal value; AST and ALT ≤2.5×upper limit of normal value; serum creatinine (Cr) ≤1.5×upper limit of normal value; (7) Voluntarily sign the informed consent form.
3. A method for evaluating the efficacy of compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The inclusion criteria for secondary prevention are as follows: (1) Patients aged between 18 and 75 years old, regardless of gender; (2) Pathologically diagnosed as gastric adenocarcinoma or colorectal adenocarcinoma; (3) Patients who have received standard chemotherapy containing platinum or irinotecan for no more than 2 cycles and who had grade I to III diarrhea in the previous cycle and recovered to grade 0 after symptomatic treatment; (4) The patient plans to receive chemotherapy with the same regimen and dose as the previous cycle; (5) WH0-PS score of 0-2; (6) Good organ function, including adequate bone marrow reserve function, good liver and kidney function: absolute neutrophil count ≥ 1.5 × 10 9 / L; platelet count ≥75×10 9 / L; serum total bilirubin ≤1×upper limit of normal value; AST and ALT ≤2.5×upper limit of normal value; serum creatinine (Cr) ≤1.5×upper limit of normal value; (7) Voluntarily sign the informed consent form.
4. A method for evaluating the efficacy of compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The medications of Group A and Group B are as follows: Group A: 3 tablets of compound glutamine enteric-coated capsules tid, starting from the first day of chemotherapy and continuing for 21 days, followed by a wash-out period and then taking the same dose of placebo, the whole cycle is 42 days; Group B: 3 tablets of placebo tid, starting from the first day of chemotherapy and continuing for 21 days. Then after a wash-out period, the same dose of compound glutamine enteric-coated capsules was taken. The whole cycle was 42 days.
5. A method for evaluating the efficacy of compound glutamine enteric-coated capsules according to claim 4, It is characterized in that The washout period is ≤14 days.
6. A method for evaluating the efficacy of compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The medications of Group C and Group D are as follows: Group C: chemotherapy with the same regimen and the same dose as the previous cycle + 3 tablets of compound glutamine enteric-coated capsules tid, 21 days; Group D: chemotherapy with the same regimen and same dose as in the previous cycle + 3 tablets of placebo tid, for 21 days.
7. A method for evaluating the efficacy of compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The observation endpoints include: (1) Primary study endpoint: overall incidence of chemotherapy-related diarrhea ≥ grade 1; (2) Secondary endpoints: the overall incidence of all gastrointestinal adverse events ≥ Grade 1 except diarrhea; the overall incidence of all gastrointestinal adverse events Grade G3 / 4; (3) Exploratory study endpoints: changes in patients' quality of life; changes in IBS-SSS scores; changes in enteritis-related serum inflammatory factors and intestinal flora.
8. A method for evaluating the efficacy of compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The observation indicators include: (1) Baseline level: gender, age, PS score, tumor differentiation, stage, biochemical indicators, and fecal flora distribution; (2) Evaluation of gastrointestinal adverse events during chemotherapy: the first time, number, frequency, duration, severity, etc. of symptoms such as vomiting, abdominal pain, diarrhea, constipation, and anorexia; (3) Fecal flora ratio detection and intestinal related inflammatory factor detection before and after treatment; (4) Treatment status: treatment method, duration of remission, recurrence, intervention-related side effects, and other chemotherapy-related adverse reactions.
9. A method for evaluating the efficacy of compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The efficacy evaluation includes: (1) The incidence and severity of chemotherapy-related gastrointestinal reactions; (2) patient quality of life assessment and weight change; (3) Changes in stool flora before and after; (4) Comparison of intestinal inflammation-related factors in serum and stool.
10. A method for evaluating the efficacy of compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The statistical hypothesis tests of Group A and Group B, and Group C and Group D involved in the primary prevention and secondary prevention need to answer two independent questions. The two hypothesis tests are performed at a significance level of bilateral α=0.05, and the required sample sizes will also be calculated separately.
Citation Information
Cited By
Multi-dimensional monitoring satiety and stomach-occupying capsule effect evaluation optimization method
CN119719690A
An optimized method for evaluating the effects of satiety and stomach-occupying capsules with multi-dimensional monitoring
CN119719690B
